SD BIOSENSOR is a South Korean in vitro diagnostics (IVD) company that develops and manufactures medical devices and reagents for infectious disease and chronic disease testing. The company operates across four main technology platforms: rapid diagnostics, fluorescence immunoassay, enzyme immunoassay, and molecular diagnostics. Its product portfolio includes the STANDARD Q rapid test kits, the STANDARD F fluorescence immunoassay analyzers, the STANDARD E ELISA and IGRA systems, and the STANDARD M and STANDARD M10 molecular diagnostic platforms. The company also offers clinical chemistry solutions via the STANDARD C brand, which focuses on HbA1c testing, and blood glucose monitoring systems under the SD GlucoNavii brand. SD BIOSENSOR serves hospitals, clinical laboratories, and public health institutions globally, with a significant presence in international public procurement markets such as those managed by the Global Fund and UNICEF. The company holds certifications from the World Health Organization, the European Union, and the US Food and Drug Administration. It maintains a global distribution network through exclusive dealers and direct sales subsidiaries in regions including India, Indonesia, Brazil, and the United States. The company's business model relies on the sale of diagnostic instruments and the recurring revenue from associated reagents and consumables.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Diagnostics & Research Homepage sdbiosensor.co.kr
Sector Healthcare IR page sdbiosensor.co.kr
Tags
in vitro diagnostics, rapid diagnostics, molecular diagnostics, immunoassay, clinical chemistry, blood glucose monitoring, infectious disease testing, chronic disease management, point-of-care testing, medical devices, STANDARD Q, STANDARD F, STANDARD E, STANDARD M, STANDARD M10, STANDARD i, STANDARD C, SD GlucoNavii, TB-Feron, SD Biosensor Healthcare Pvt Ltd., PT. SD Biosensor Healthcare, ECO Diagnostica Ltda., Bestbion dx GmbH, Mirero Corp., Meridian Bioscience
Press page —

Metrics

Valuation  
Market cap ₩ 994.081B
Market cap (USD) $ 731.626M
P/E -1.34
PEG —
P/BV 0.41
P/S 1.35
P/OCF 17.52
P/FCF 89.32
Dividend yield —
Turnover / mcap —
Returns  
ROE -19.5%
ROI -22.0%
ROIC -2.6%
Profit margin -72.1%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y No
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock —
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) —
Quality score -57.1%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Revenue 710.581B 694.574B 655.677B 2.932T 2.93T
Net profit -512.106B -98.411B -467.712B 911.362B 1.088T
Free cash flow 300.431B 77.744B -384.884B 591.894B 1.138T

Filed figures

Figure Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (KRW) 208B 108B 141B 136B 138B
↳ YoY growth -48.0% +30.1% -2.9% +1.2%
Borrowings, current (KRW) 0.00 450M 129B — 1.57B
Borrowings, non-current (KRW) 275M 147M 282B 338B 347B
Lease liabilities (KRW) 24.7B 24.2B 12.7B 20.2B 17B
Cash and deposits (KRW) 882B 1.87T 482B 177B 367B
Intangible assets (KRW) 38B 67.4B 1.94T 2.09T 1.26T
Net debt (borrowings + leases - cash) (KRW) -857B -1.85T -58B 180B -2.96B
Cash flow detail
Operating cash flow (KRW) 1.23T 889B -242B 157B 358B
Purchases of property, plant and equipment (KRW) -97.3B -297B -143B -78.8B -57.1B
Purchases of intangible assets (KRW) -1.98B -3.34B -2.12B -2.12B -404M
Dividends paid (cash effect) (KRW) -49.8B -199B -29.5B -38.1M -24.2B
Share buybacks (cash effect) (KRW) -99.6B 0.00 0.00 -18.4B -11.6B
Interest paid (cash effect) (KRW) -498M -985M -191B -31.9B -25.7B
Income taxes paid (cash effect) (KRW) -133B -537B -199B 84.5B 338B
Free cash flow (OCF - PPE - intangibles) (KRW) 1.14T 589B -387B 75.6B 300B
Income detail
Total comprehensive income (KRW) 1.09T 912B -396B 118B -561B
Comprehensive income to owners (KRW) 1.09T 915B -396B 117B -559B
Reported Aug 22, 2025 Aug 22, 2025 Aug 22, 2025 Aug 22, 2025 May 14, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

분기보고서 (2026.09) Bull 0 Bear 0 Routine
[기재정정]주요사항보고서(자기주식취득결정) Bull 2 Bear 0 Capital return
주요사항보고서(자기주식취득결정) Bull 3 Bear 0 Capital return

Prompts

SD BIOSENSOR (ticker 137310), listed in South Korea.

ETFs Holding SD BIOSENSOR

ETF Weight in ETF Shares Market value As of
AVEE 0.01% 2,479 $ 13.804K Nov 16, 2026
DFEM 0.00% 54,883 $ 292.06K Nov 12, 2026
DEXC 0.00% 808 $ 4,299.78 Nov 12, 2026
AVEM 0.00% 41,043 $ 228.545K Nov 16, 2026
AVES 0.00% 1,247 $ 6,943.82 Nov 16, 2026
AVSE 0.00% 1,269 $ 7,066.32 Nov 16, 2026
AVXC 0.00% 70 $ 389.79 Nov 16, 2026